Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa-2a +/- Isotretinoin in Metastatic Renal Cell Carcinoma
NCT00002737Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 1996
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of isotretinoin in renal cell carcinoma (RCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective Response Rate. Started Mar 1996; status: completed.
02
Drugs
isotretinoin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00002737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002737.